University of California, Los Angeles
The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
This double-blind placebo controlled, within-subject study study will assess testing devices that can measure biochemical markers in oral fluid and neurocognitive-performance markers of recent THC or CBD use. Other pharmacodynamic effects of oral THC or CBD will be determined and the pharmacokinetics of THC, CBD, and respective metabolites will be assessed in whole blood.
Inclusion Criteria: * Male or non-pregnant and non-lactating females aged 21-55 years * Report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening, * Not currently seeking treatment for their cannabis use * Have a Body Mass Index from 18.5 - 34kg/m2. * Able to perform all study procedures * Must be using a contraceptive (hormonal or barrier methods) Exclusion Criteria: * Meeting DSM-V criteria for moderate to severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine * Any other Axis I disorder * Report using other illi…
Oral placebo
Oral THC (20 mg)
Oral CBD (20 mg)
Oral THC (20 mg) + CBD (20 mg)
Arctuva estimate
Verify or correct the compensation shown for this listing.